Portola Pharmaceuticals Announces Presentation of Interim Results from Phase 3b/4 ANNEXA™-4 Study of AndexXa™ (andexanet alfa) at ...
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that interim results from its ongoing Phase 3b/4 ANNEXA™-4 trial of AndexXa™ (andexanet alfa), a Factor Xa inhibitor antidote, will …